Latest Safety News

Hawsons Iron Ltd confirms the technical viability of a fully dry processing circuit for its Hawsons Iron Project, promising cost and environmental benefits. An updated prefeasibility study and maiden ore reserves are expected soon.

Zelira Therapeutics has published full results from a Phase I study showing its cannabinoid-based therapy ZLT-L-007 significantly outperforms Lyrica® in managing diabetic neuropathy pain and related symptoms.

Lincoln Minerals’ Kookaburra Graphite Project has delivered battery-grade graphite purity exceeding 99.95%, confirming its suitability for lithium-ion battery anodes through a safer, hydrofluoric acid-free process.

Australian Agricultural Company Limited (AACo) reported a robust FY25 operating profit of $58.4 million, driven by increased meat and cattle sales volumes and strategic brand growth despite inflationary pressures.

Nufarm Limited reported a 3% revenue increase and a 17% rise in underlying EBIT for HY25, driven by strong crop protection volumes and improved cost management. However, net debt climbed 12%, pushing leverage to 4.5 times, highlighting ongoing financial balancing acts.

Chimeric Therapeutics has progressed its CHM CDH17 CAR-T cell therapy clinical trial to Dose Level 2 after completing Dose Level 1 with no safety concerns, showing encouraging early signs of activity in advanced gastrointestinal cancers.

Nufarm Limited reported a solid half-year performance with a 3% revenue increase and a 40% jump in underlying EBIT, driven by strong crop protection sales and cost improvements. However, net debt rose 12%, reflecting investments in omega-3 production and seed technology expansion.

SGH Ltd has reaffirmed its FY25 guidance for high single-digit EBIT growth while targeting a net debt to EBITDA ratio of 2.0x by year-end, underpinned by disciplined capital allocation and operational improvements across its diversified industrial, energy, and media businesses.

Spacetalk Ltd reports robust 3QFY25 results, showcasing strong revenue growth and a sharp reduction in losses as it pivots to a subscription-driven family safety platform.

Clarity Pharmaceuticals has initiated its second registrational Phase III AMPLIFY trial for the Cu-SAR-bisPSMA PET imaging agent targeting biochemical recurrence of prostate cancer. The multi-centre study aims to generate critical data supporting FDA approval and could redefine prostate cancer diagnostics.

Breakthrough Minerals has resolved a critical regulatory issue allowing the Errolls Gold Project acquisition to proceed, with drilling set to begin next quarter targeting high-grade gold extensions.

FFI Holdings Limited has announced a pro-rata non-renounceable entitlement offer priced at $3.50 per share, aiming to raise approximately $11 million to support its food manufacturing growth and property investments. The offer closes on 17 June 2025 and is open to eligible shareholders in Australia and New Zealand.